B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome
B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …
Cell cycle on the crossroad of tumorigenesis and cancer therapy
Aberrancy in cell cycle progression is one of the fundamental mechanisms underlying
tumorigenesis, making regulators of the cell cycle machinery rational anticancer therapeutic …
tumorigenesis, making regulators of the cell cycle machinery rational anticancer therapeutic …
Mechanisms of cancer metastasis
M Castaneda, P den Hollander, NA Kuburich… - Seminars in cancer …, 2022 - Elsevier
Metastatic cancer is almost always terminal, and more than 90% of cancer deaths result from
metastatic disease. Combating cancer metastasis and post-therapeutic recurrence …
metastatic disease. Combating cancer metastasis and post-therapeutic recurrence …
Mechanisms of immunotherapy resistance: lessons from glioblastoma
CM Jackson, J Choi, M Lim - Nature immunology, 2019 - nature.com
Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …
Immunogenic cell death in cancer therapy: Present and emerging inducers
J Zhou, G Wang, Y Chen, H Wang… - Journal of cellular and …, 2019 - Wiley Online Library
In the tumour microenvironment (TME), immunogenic cell death (ICD) plays a major role in
stimulating the dysfunctional antitumour immune system. Chronic exposure of damage …
stimulating the dysfunctional antitumour immune system. Chronic exposure of damage …
Oncolytic virus immunotherapy: future prospects for oncology
J Raja, JM Ludwig, SN Gettinger, KA Schalper… - … for immunotherapy of …, 2018 - Springer
Background Immunotherapy is at the forefront of modern oncologic care. Various novel
therapies have targeted all three layers of tumor biology: tumor, niche, and immune system …
therapies have targeted all three layers of tumor biology: tumor, niche, and immune system …
The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer
X Liu, S Wu, Y Yang, M Zhao, G Zhu, Z Hou - Biomedicine & …, 2017 - Elsevier
Tumor-infiltrating immune cells are closely associated with clinical outcome. However,
immunohistochemistry-based analysis of tumor infiltrates can be misleading as the …
immunohistochemistry-based analysis of tumor infiltrates can be misleading as the …
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
BA Wilky - Immunological reviews, 2019 - Wiley Online Library
Immune checkpoint inhibitors (ICIs) have revolutionized our approach to cancer treatment in
the past decade. While monoclonal antibodies to CTLA‐4 and PD‐1/PD‐L1 have produced …
the past decade. While monoclonal antibodies to CTLA‐4 and PD‐1/PD‐L1 have produced …
[HTML][HTML] Pas de deux: control of anti-tumor immunity by cancer-associated inflammation
S Shalapour, M Karin - Immunity, 2019 - cell.com
In many settings, tumor-associated inflammation, supported mainly by innate immune cells,
contributes to tumor growth. Initial innate activation triggers secretion of inflammatory …
contributes to tumor growth. Initial innate activation triggers secretion of inflammatory …
[HTML][HTML] The role of lipid metabolic reprogramming in tumor microenvironment
K Yang, X Wang, C Song, Z He, R Wang, Y Xu… - Theranostics, 2023 - ncbi.nlm.nih.gov
Metabolic reprogramming is one of the most important hallmarks of malignant tumors.
Specifically, lipid metabolic reprogramming has marked impacts on cancer progression and …
Specifically, lipid metabolic reprogramming has marked impacts on cancer progression and …